hPSCreg®
This website uses cookies to keep track of login sessions and for internal Matomo Statistics. See our Privacy Policy for details. This website uses cookies, learn more


JHUi009-A-1

Registration Summary:

JHU004, Clone F6

The cell line is not validated yet.
JHUi009-A-1

General

Cell Line
hPSCreg name JHUi009-A-1
Cite as:
JHUi009-A-1
Alternative name(s)
JHU004, Clone F6
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 30th September 2025
Notes Isogenic, normal control for JHUi009-A
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider
Generator Johns Hopkins University (JHU)
Owner School of Medicine
Distributors
Derivation country United States

External Databases
BioSamples SAMEA120102804

General Information
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed
Subclone of

Donor Information

General Donor Information
Sex male
Ethnicity White/Caucasian

Phenotype and Disease related information (Donor)
Diseases A disease was diagnosed.
Ehlers-Danlos syndrome, vascular type
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • EDS IV
  • EDS type 4
  • Ehlers-Danlos syndrome type 4
  • Ehlers-Danlos syndrome type IV
  • Ehlers-Danlos syndrome, type IV
  • Ehlers-Danlos syndrome, vascular type
  • sack-Barabas syndrome
  • EDS IV (formerly)
  • EDS type 4 (formerly)
  • EDS4 (formerly)
  • Ehlers Danlos syndrome, arterial type
  • Ehlers Danlos syndrome, ecchymotic type
  • Ehlers Danlos syndrome, sack-Barabas type
  • Ehlers-Danlos syndrome type 4 (formerly)
  • Ehlers-Danlos syndrome type IV (formerly)
  • vEDS
  • vascular EDS
  • vascular Ehlers-Danlos syndrome
show more synonyms
Genetic variants
2q32.2
NM_000090.4(COL3A1):c.2456G>A (p.Gly819Asp)
NP_000081.2:p.Gly819Asp
Heterozygous
Family history Unavailable
Is the medical history available upon request? No
Is clinical information available? No

Other Genotyping (Donor)
Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)
BioSamples SAMEA118339864

Ethics

Also have a look at the ethics information for the parental line JHUi009-A .
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Synthego was contracted to perform the gene editing of line JHUi009-A to generate this normal isogenic control line
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General
The source cell information can be found in the parental cell line JHUi009-A.

Reprogramming method

Vector free reprogramming

Other
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Accutase, TrypLE or EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
NANOG
Yes
–
–
POU5F1 (OCT-4)
Yes
–
–
SOX2
Yes
–
Morphology pictures
JHU004 F6 20x BF.tif
Representative image of JHUi009-A-1 cultivated on a geltrex-coated well of a 6-well plate in E8 medium
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Marker Expressed
FoxA2 forkhead protein
Yes
GATA4 zinc finger transcription factor
Yes
Sox17 Sry box transcription factor
Yes
Protocol or reference
JHU004 F6 Endoderm.jpg
qPCR analysis of the indicated endodermal markers
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
Heart and Neural Crest Derivatives Expressed 1
Yes
Brachyury - T-box transcription factor T
Yes
NKX2-5 homeobox transcription factor
Yes
Protocol or reference
JHU004 F6 Mesoderm.jpg
qPCR analysis of selected mesodermal markers
JHU004 F6 Mesoderm.jpg
qPCR analysis of selected mesodermal markers
JHU004 F6 Mesoderm.jpg
qPCR analysis of selected mesodermal markers
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
OTX2 homeobox
Yes
Pax6 paired box TF
Yes
Sox1 transcription factor
Yes
Protocol or reference
JHU004 F6 Ectoderm.jpg
qPCR analysis of selected ectodermal markers
JHU004 F6 Ectoderm.jpg
qPCR analysis of selected ectodermal markers

Microbiology / Virus Screening

Genotyping

Karyotyping (Cell Line)
Has the cell line karyotype been analysed?
Yes
46, XY
JHUi009-A-1_Karyostat_Report.jpg
Passage number: p41
Karyotyping method: Karyostat (ThermoFisher)

Other Genotyping (Cell Line)

Genetic Modification

Disease/phenotype related modifications
Vascular type Ehlers-Danlos syndrome
This line serves as an isogenic normal control line for JHUi009-A, which contains a gene mutation. This gene edited control is normal, and details are provided below, since this gene mutation should not lead to a disease phenotype
Synonyms
  • Ehlers-Danlos syndrome type 4
  • Ehlers-Danlos syndrome type IV
  • autosomal dominant type IV Ehlers-Danlos syndrome
Genetic modifications
Isogenic modification
2q32.2
NM_000090.4(COL3A1):c.2456A>G (p.Asp819Gly)
NP_000081.2:p.Asp819Gly
Homozygous
Following gene editing via CRISPR/Cas9 mediated events, Sanger sequencing was performed to show that the disease gene mutation (c.2456G>A) had been corrected to a wild-type form (c.2456A). Since this sequence is wt, it is listed below under Genetic Modifications which are not disease related i.e., corrected.
Repaired
Genetic modifications not related to a disease
Isogenic modification
2q32.2
NM_000090.4(COL3A1):c.2456A>G (p.Asp819Gly)
NP_000081.2:p.Asp819Gly
Homozygous
Following gene editing via CRISPR/Cas9 mediated events, Sanger sequencing was performed to show that the disease gene mutation had been corrected to a wild-type form
Repaired